NASDAQ

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 4 April 2025.Renovaro Biosciences (NASDAQ:RENB) announced that Predictive Oncology (NASDAQ: POAI) terminated their merger agreement, which Renovaro claims is a breach of binding agreements. Renovaro is demanding compliance with the deal, including an exclusive license agreement, and may pursue legal action if unNeuroOne Medical (NASDAQ: NMTC) announced the pricing of an US$8 million underwritten registered public offering of 16m shares of its common stock for US$0.50 per share. Shares closed down 45% at US$0.48.Sarepta Therapeutics (NASDAQ: SRPT) reported that an independent data monitoring committee reviewed safety data for ELEVIDYS after EU regulators flagged liver failure concerns. The committee upheld a favorable benefit-risk profile, allowing paused trials to continue. Sarepta and Roche will submit fiSangamo Therapeutics (NASDAQ: SGMO) licensed its STAC-BBB AAV capsid to Eli Lilly for CNS disease treatments, securing an US$18 million upfront fee and potential milestone payments up to US$1.4 billion, plus tiered royalties on future sales. Shares closed up 6% at US$0.66.Dynavax Technologies (NASDAQ: DVAX) filed preliminary proxy materials ahead of its 2025 annual meeting, highlighting ongoing strategy execution and nominating four independent directors (Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun) for reelection. Shares closed down 2% at US$12.6Arvinas (NASDAQ: ARVN) reported first-in-human Phase 1 data for ARV-102, showing it was well tolerated and achieved robust, dose-dependent LRRK2 degradation in CSF and blood, supporting continued development in Parkinson’s and related neurodegenerative diseases. Shares closed down 5% at US$6.56.OS Therapies (NASDAQ: OSTX) received a Buy rating and a US$19.00 price target from Lake Street. Shares closed down 9% at US$1.4.

V小姐

3 months ago

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 25 April 2025. Summit Therapeutics (NASDAQ: SMMT) shares closed down 36% at US$23.47 despite China approving Akeso’s ivonescimab (AK112) as a first-line lung cancer monotherapy after a Phase 3 trial showed superior progression-free Molecular Partners (NASDAQ: MOLN) shares traded up 22% at US$5.12 after MP0712, a ²¹²Pb-labeled Radio-DARPin targeting DLL3 for small-cell lung cancer, demonstrated strong preclinical efficacy and safety, with first- VYNE Therapeutics (NASDAQ: VYNE) reported that the FDA verbally informed VYNE Therapeutics that it had placed a clinical hold on the company’s Phase 1b study evaluating VYN202 for treating moderate-to-severe plaque p Acrivon Therapeutics (NASDAQ: ACRV) will present preclinical data at AACR 2025 showing how ACR-2316 a clinical-stage, AP3-enabled WEE1/PKMYT1 inhibitor drives potent single-agent tumor cell death by inducing mitotic BriaCell Therapeutics (NASDAQ: BCTX) priced a US$13.8m public offering of 3.1m units at US$4.50 each, with each unit consisting of one common share and one warrant exercisable at US$5.25. The company intends to use t Lexaria Bioscience (NASDAQ: LEXX) announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 2.0m shares of common stock at a purchase price of US$1.00 Cyclacel Pharmaceuticals (NASDAQ: CYCC) issued a US$0.15 per share quarterly dividend payable on 1st May to shareholders recorded by 29th April, the ex-dividend date. Separately, Cyclacel Pharmaceuticals has been gra

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 29 May 2025. Alzamend Neuro (NASDAQ: ALZN) reported that the initial subject in the Phase II “Lithium-in-Brain” trial has received its dosage of AL001 for comparison against lithium carbonate. The study’s primary findings are antic Revelation Biosciences (NASDAQ: REVB) priced a US$4m public offering of 3.64m shares (or equivalents) and warrants for up to 14.56m shares at US$1.10 per share and warrant. Warrants are exercisable at US$1.10 upon stoc IMUNON (NASDAQ: IMNN) completed a US$3.25m private placement by selling 7,222,223 common shares and short-term warrants for an additional 14,444,446 shares at US$0.45 per share. The warrants could generate up to US$6.5 Applied DNA Sciences (NASDAQ: APDN) will implement a 1‑for‑15 reverse stock split effective 2 June 2025. Shares closed down 37% at US$0.33. Intensity Therapeutics (NASDAQ: INTS) will showcase a Trials‑in‑Progress poster on its Phase 3 INVINCIBLE‑3 study of intratumoral INT230‑6 in metastatic soft‑tissue sarcoma at ASCO 2025. Shares closed up 34% at US$0.39 ORIC Pharmaceuticals (NASDAQ: ORIC) reported Phase 1b data for ORIC-944 in mCRPC, with 59% PSA50 and 24% PSA90 confirmed response rates. They also secured approximately US$125m via a private placement at US$6.50 per sh Immunic (NASDAQ: IMUX) announced the pricing of a public offering including pre-funded warrants exercisable immediately, Series A warrants exercisable until 31 December 2025, and Series B warrants exercisable starting Intellia Therapeutics (NASDAQ: NTLA) shares are currently down during premarket hours after reporting a Grade 4 liver enzyme elevation in a patient in the late-stage MAGNITUDE trial for its Regeneron (NASDAQ: REGN)-par